Arbutus Biopharma (ABUS) News Today $3.42 -0.02 (-0.49%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$3.45 +0.03 (+0.76%) As of 02/21/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Critical Analysis: Arbutus Biopharma (NASDAQ:ABUS) vs. Incannex Healthcare (NASDAQ:IXHL)February 17, 2025 | americanbankingnews.comIs Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy?February 12, 2025 | msn.com10 Best Nasdaq Stocks Under $5 to BuyFebruary 11, 2025 | insidermonkey.comArbutus Biopharma's CFO David Hastings sells shares worth $72,826February 5, 2025 | msn.comPositive Outlook for Arbutus Biopharma: Promising Developments and Financial Strength Justify Buy RatingJanuary 21, 2025 | markets.businessinsider.comArbutus Biopharma (NASDAQ:ABUS) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $5.00 target price on shares of Arbutus Biopharma in a report on Tuesday.January 21, 2025 | marketbeat.comJim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’January 16, 2025 | msn.comArbutus Biopharma: Strategic Advancements and Strong Financial Outlook Support Buy RatingJanuary 15, 2025 | markets.businessinsider.comBarclays PLC Purchases 223,995 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)Barclays PLC raised its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 466.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 272,029 shares of the biopharmaceutical company's stock after buying an additJanuary 15, 2025 | marketbeat.comArbutus Biopharma Corporation: Arbutus Provides 2025 Corporate and Financial UpdateJanuary 13, 2025 | finanznachrichten.deArbutus Biopharma provides 2025 corporate, financial updateJanuary 13, 2025 | markets.businessinsider.comArbutus expects to significantly reduce its net cash burn in 2025January 13, 2025 | msn.comArbutus Provides 2025 Corporate and Financial UpdateJanuary 13, 2025 | globenewswire.comArbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase - Here's What HappenedArbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading Volume - What's Next?January 7, 2025 | marketbeat.comArbutus: Positive Imdusiran Data Leads To Phase 2B DevelopmentJanuary 7, 2025 | seekingalpha.comState Street Corp Purchases 1,472,652 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)State Street Corp lifted its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 50.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,407,133 shares of the biopharmaceutiDecember 25, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 195,843December 20, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Shares Gap Down - Here's WhyArbutus Biopharma (NASDAQ:ABUS) Shares Gap Down - Should You Sell?December 16, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Grows Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)Charles Schwab Investment Management Inc. raised its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 218.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,212,246 shares of the biopharmaDecember 14, 2024 | marketbeat.comHere’s Why Arbutus (ABUS) Surged in Q3December 6, 2024 | msn.comInvestor urges Bucks County firm Arbutus to seek partner over sale of stockDecember 5, 2024 | bizjournals.comWhitefort Capital Sends Letter To Arbutus Board; Requests MeetingDecember 3, 2024 | markets.businessinsider.comWhitefort Capital sends letter to Arbutus Biopharma board of directorsDecember 3, 2024 | markets.businessinsider.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest UpdateArbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the recipient of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 6,060,000 shares, a decline of 7.3% from the October 31st total of 6,540,000 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is currently 5.3 days.December 2, 2024 | marketbeat.comJoin Arbutus Biopharma for Virtual Fireside Chat!November 30, 2024 | msn.comArbutus Biopharma Highlights Hepatitis B Treatment AdvancesNovember 26, 2024 | markets.businessinsider.comArbutus to Participate in H.C Wainwright @ Home Virtual Fireside ChatNovember 26, 2024 | globenewswire.comArbutus Biopharma (NASDAQ:ABUS) Stock Quotes, Forecast and News SummaryNovember 20, 2024 | benzinga.comArbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from Chardan CapitalChardan Capital restated a "buy" rating and set a $5.00 price objective on shares of Arbutus Biopharma in a report on Wednesday.November 20, 2024 | marketbeat.comArbutus Biopharma’s Promising Clinical Trial Results Lead to Buy RatingNovember 20, 2024 | markets.businessinsider.comArbutus Biopharma price target raised to $5 from $4.50 at ChardanNovember 20, 2024 | markets.businessinsider.comArbutus Biopharma’s Promising Breakthrough in Chronic Hepatitis B Treatment Justifies Buy RatingNovember 18, 2024 | markets.businessinsider.comArbutus Biopharma: Promising Developments and Positive Outlook Boost Buy RatingNovember 18, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS)HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research note on Monday.November 18, 2024 | marketbeat.comArbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B TreatmentNovember 17, 2024 | msn.comArbutus Biopharma’s Promising cHBV Treatment ResultsNovember 16, 2024 | markets.businessinsider.comArbutus Biopharma’s Trial Boosts Hepatitis B TreatmentNovember 16, 2024 | markets.businessinsider.comArbutus Biopharma to Showcase Innovations at Jefferies London Healthcare ConferenceNovember 16, 2024 | msn.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 16.0% in OctoberArbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 6,540,000 shares, a drop of 16.0% from the October 15th total of 7,790,000 shares. Based on an average trading volume of 1,100,000 shares, the days-to-cover ratio is currently 5.9 days.November 16, 2024 | marketbeat.comArbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of InterferonNovember 15, 2024 | markets.businessinsider.comArbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of InterferonNovember 15, 2024 | globenewswire.comArbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis BNovember 15, 2024 | globenewswire.comArbutus Biopharma to Present at Jefferies ConferenceNovember 15, 2024 | markets.businessinsider.comArbutus to Present at Jefferies London Healthcare ConferenceNovember 14, 2024 | globenewswire.comArbutus Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 14, 2024 | theglobeandmail.comHC Wainwright Expects Weaker Earnings for Arbutus BiopharmaArbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - Stock analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Arbutus Biopharma in a note issued to investors on Thursday, November 7th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutNovember 11, 2024 | marketbeat.comArbutus Biopharma Advances Clinical Trials and Strengthens Financial Position in Q3 2024November 9, 2024 | msn.comArbutus Biopharma’s Promise and Risks: A Hold Rating Amid Early Trial Success and Legal UncertaintyNovember 9, 2024 | markets.businessinsider.comPromising Potential of Arbutus Biopharma’s Imdusiran in Achieving Functional Cure for Hepatitis B: Ed Arce’s Buy RatingNovember 7, 2024 | markets.businessinsider.comArbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research note on Thursday.November 7, 2024 | marketbeat.com Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address ABUS Media Mentions By Week ABUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABUS News Sentiment▼0.000.60▲Average Medical News Sentiment ABUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABUS Articles This Week▼13▲ABUS Articles Average Week Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HCM News EWTX News MIRM News AMRX News KYMR News GMTX News PTGX News MESO News CNTA News BHC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABUS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABUS Stock Alerts